Alvotech_logo.jpg
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
03 avr. 2024 07h41 HE | Alvotech
REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Hosts Audio
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
03 avr. 2024 06h43 HE | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a...
Alvotech streymir ky
Alvotech streymir kynningu fyrir fjárfesta 3. apríl 2024 kl. 12:15 að íslenskum tíma
03 avr. 2024 06h43 HE | Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið myndi streyma stuttri kynningu fyrir fjárfesta kl. 12:15 að íslenskum tíma í dag, 3. apríl 2024. Anil Okay, framkvæmdastjóri viðskipta mun þar...
Alvotech_logo.jpg
Alvotech Announces Increase in Number of Own Shares
22 mars 2024 16h15 HE | Alvotech
Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share...
Alvotech_logo.jpg
Alvotech tilkynnir um útgáfu eigin hlutabréfa
22 mars 2024 16h15 HE | Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að stjórn fyrirtækisins hefði ákveðið að gefa út þrettán milljón (13.000.000) nýja almenna hluti í félaginu. Dótturfélag Alvotech, Alvotech Manco ehf....
Alvotech_logo.jpg
Alvotech Announces Increase in Number of Own Shares
22 mars 2024 16h15 HE | Alvotech
REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
Alvotech Reports Fin
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
20 mars 2024 16h15 HE | Alvotech
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...
Alvotech Reports Fin
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
20 mars 2024 16h15 HE | Alvotech
 Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...
Alvotech birtir uppg
Alvotech birtir uppgjör fyrir árið 2023 og kynnir nýjustu áfanga í rekstri félagsins
20 mars 2024 16h15 HE | Alvotech
Heildartekjur á árinu 2023 voru 93,4 milljónir dollara, sem er 10% aukning frá fyrra áriSölutekjur á árinu 2023 voru 48,7 milljónir dollara, samanborið við 24,8 milljónir dollara á árinu 2022, og voru...
Alvotech Announces W
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
05 mars 2024 16h01 HE | Alvotech
Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024  Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar...